Comment
Author: Admin | 2025-04-28
Here.6. LemtradaLemtrada, manufactured by Genzyme (a Sanofi company), is a disease modifying therapy for people with relapsing-remitting forms of multiple sclerosis (RRMS). Biologically, it is a humanized monoclonal antibody aimed at specific receptors on the surface of immune cells to modulate immune responses. Although approved by the U.S. Food and Drug Administration (FDA), the agency recommends its use be restricted to RRMS patients who have had an inadequate response to two or more MS therapies.Learn more about Lemtrada here.7. PlegridyPeginterferon beta-1a, known by its brand name Plegridy, is an approved treatment for relapsing and remitting forms of multiple sclerosis (RRMS). The drug is a “pegylated” form of interferon beta-1a, meaning polyethylene glycol (PEG) attaches to interferon molecules so as to enable them to maintain biologic effects for longer periods of time, allowing for less frequent dosing. It is an injectable formulation, administered subcutaneously, once every two weeks. Biogen Idec is responsible for clinical development and marketing of the drug in the United States and the European Union.Learn more about Plegridy here.8. Tecfidera (dimethyl fumarate)Tecfidera0 (dimethyl fumarate, DMF) is an oral formulation approved by the U.S. Food and Drug Administration (FDA) for relapsing-remitting forms of multiple sclerosis (MS). It has also been studied and used to treat several forms of inflammatory diseases, such sarcoidosis, psoriasis, and necrobiosis lipoidic. Clinical trials of Tecfidera demonstrated its immunomodulatory effects in MS patients, where it was seen to significantly reduce relapse rates and to increase the time of disease progression compared to a placebo. Despite its immunomodulatory properties, it does not induce immune suppression.Learn more about Tecfidera (dimethyl fumarate) here.9. Tysabri (Natalizumab)Natalizumab (manufactured by Biogen Idec as Tysabri; previously named Antegren) is a humanized monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) as a monotherapy for the treatment of relapsing-remitting forms of multiple sclerosis (MS) and Crohn’s disease. Administered as an intravenous injection, the drug is believed to reduce or inhibit the ability of immune cells to invade the blood-brain barrier, protecting against autoimmune attacks by the body’s innate immune system to slow the worsening of symptoms and number of disease flares.Tysabri is also approved as a disease-modifying monotherapy in the European Union (since 2006) for relapsing MS patients with high disease activity (two or more lesions in one year) despite treatment with a β-interferon or glatiramer acetate, and for those with rapidly evolving severe RRMS.Learn more about Tysabri (Natalizumab) here.By Andreia
Add Comment